Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Mary E. Gordinier"'
Autor:
Mary E. Gordinier, Alpa Nick, Anca Chelariu-Raicu, Carola Leuschner, John K. Whisnant, Linda M Bavisotto, Renata R. Urban, Robert L. Coleman, Graziela Zibetti Dal Molin
Publikováno v:
Gynecologic Oncology. 160:418-426
Objective This randomized open-label phase II study evaluated the safety and clinical activity of EP-100 plus weekly paclitaxel in patients with recurrent ovarian cancer expressing positive LHRH receptor. Methods In a limited “run-in” dose escala
Autor:
Stephen Fiascone, Mary E. Gordinier, Ashley Stuckey, Amy Brown, Katina Robison, Christina Raker, Melissa A. Clark, Emily K. Hill
Publikováno v:
Journal of Minimally Invasive Gynecology. 26:1088-1094
STUDY OBJECTIVE To compare the parenting and career patterns of female and male gynecology subspecialists. DESIGN Cross-sectional survey study (Canadian Task Force classification II-3). SETTING Survey administered electronically in February 2015 to p
Autor:
Charles N. Landen, Ronald J. Buckanovich, Michael Sill, Robert S. Mannel, Joan L. Walker, Paul Disilvestro, Cara Amanda Mathews, David Gardner Mutch, Marcia Hernandez, Lainie P. Martin, Erin Bishop, Sarah Gill, Mary E Gordinier, Robert Allen Burger, Carol Aghajanian, Joyce F. Liu, Kathleen N. Moore, Michael A. Bookman
Publikováno v:
Journal of Clinical Oncology. 40:5501-5501
5501 Background: The Interleukin-6/JAK/STAT3 axis, via an increase in cancer stem-like cell (CSC) survival, is a reported driver of chemotherapy resistance. We hypothesized that addition of the JAK1/2 inhibitor ruxolitinib to standard chemotherapy wo
Publikováno v:
Gynecologic and obstetric investigation. 86(5)
Objectives: Sexual trauma poses a significant concern and is associated with heightened stress, negative health repercussions, and adverse economic effects. A history of abuse may increase a woman’s risk of developing cancer, in particular cervical
Autor:
Lisa B E Shields, Mary E. Gordinier
Publikováno v:
Gynecologic and obstetric investigation. 84(1)
Advanced vulvar cancer is associated with a very poor prognosis. Surgical resection is the mainstay of treatment, with radiation indicated for areas at high risk for recurrence. When surgical and radiation options have been exhausted, the effectivene
Autor:
Mary E. Gordinier, Christina Raker, Melissa A. Clark, Emily K. Hill, A.K. Brown, Stephen Fiascone, Christine Luis, Ashley Stuckey, Katina Robison
Publikováno v:
Clinical Obstetrics, Gynecology and Reproductive Medicine. 3
Autor:
Mary E. Gordinier, Carol Hanchette
Publikováno v:
International Journal of Applied Geospatial Research. 1:67-79
From 1995-2005, ovarian cancer accounted for 2.7% of new cancer cases diagnosed among women in Kentucky and was responsible for 4.7% of female cancer deaths in the state. The five-year survival rate for ovarian cancer is 45% for all stages combined.
Autor:
Mary E. Gordinier, C. R. Toler, C. W. Helm, Daniel S. Metzinger, Lynn P. Parker, Robert P. Edwards, R. S. Martin
Publikováno v:
International Journal of Gynecologic Cancer. 17:204-209
Our experience with hyperthermic intraperitoneal chemotherapy (IPHC) in conjunction with surgical resection for endometrial cancer recurrent within the abdominal cavity was reviewed. Eligible patients underwent exploratory laparotomy with the aim of
Autor:
Jane Miller, Leslie Pires, Trevor Tejada-Berges, Mary E. Gordinier, Don S. Dizon, Robert D. Legare, Cornelius O. Granai, Paul DiSilvestro, Joanna Schwartz, Sherry Weitzen, Adam Rojan, Richard G. Moore
Publikováno v:
Gynecologic Oncology. 100:417-421
Although the standard of care for advanced epithelial ovarian cancer (EOC) is six cycles (6C) of platinum-taxane (PT), there have been no studies on the optimal duration of treatment in the era of adjuvant taxanes. At our center, some women receive e
Autor:
Mary E. Gordinier, Don S. Dizon
Publikováno v:
Annals of Pharmacotherapy. 39:962-965
OBJECTIVE:To detail the dyspnea encountered in women receiving thalidomide as therapy for advanced ovarian cancer.CASE SUMMARIES:Eight of 18 (44%) patients with recurrent ovarian cancer developed dyspnea while receiving thalidomide 200 mg daily as pa